Eagle Pharmaceuticals, Inc. (EGRX)
USD 1.62
(-10.0%)
USD 1.62
(-10.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | 53.45 Million USD | 1935.02% |
| 2021 | -2.91 Million USD | -111.53% |
| 2020 | 25.25 Million USD | 15.76% |
| 2019 | 21.81 Million USD | -40.42% |
| 2018 | 36.61 Million USD | -50.51% |
| 2017 | 73.99 Million USD | 38.69% |
| 2016 | 53.35 Million USD | 1984.02% |
| 2015 | 2.56 Million USD | 113.65% |
| 2014 | -18.75 Million USD | -121.84% |
| 2013 | -8.45 Million USD | 57.36% |
| 2012 | -19.83 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q2 | 10.3 Million USD | 66.54% |
| 2023 Q1 | 6.18 Million USD | -34.64% |
| 2022 Q1 | 59.82 Million USD | 914.22% |
| 2022 FY | 53.45 Million USD | 1935.02% |
| 2022 Q2 | 2.2 Million USD | -96.32% |
| 2022 Q3 | -2.3 Million USD | -204.68% |
| 2022 Q4 | 9.46 Million USD | 510.49% |
| 2021 FY | -2.91 Million USD | -111.53% |
| 2021 Q3 | -10.17 Million USD | -194.06% |
| 2021 Q4 | 5.89 Million USD | 157.96% |
| 2021 Q2 | 10.82 Million USD | 386.77% |
| 2021 Q1 | -3.77 Million USD | -138.53% |
| 2020 Q3 | 15.41 Million USD | 315.66% |
| 2020 Q1 | 4.03 Million USD | 39.28% |
| 2020 Q2 | 3.7 Million USD | -8.08% |
| 2020 Q4 | 9.79 Million USD | -36.48% |
| 2020 FY | 25.25 Million USD | 15.76% |
| 2019 Q2 | 9.23 Million USD | -24.13% |
| 2019 Q4 | 2.89 Million USD | 216.63% |
| 2019 Q3 | -2.48 Million USD | -126.9% |
| 2019 FY | 21.81 Million USD | -40.42% |
| 2019 Q1 | 12.16 Million USD | -22.64% |
| 2018 Q3 | 18.4 Million USD | 9955.74% |
| 2018 Q2 | 183 Thousand USD | -92.06% |
| 2018 Q1 | 2.3 Million USD | -77.92% |
| 2018 FY | 36.61 Million USD | -50.51% |
| 2018 Q4 | 15.73 Million USD | -14.52% |
| 2017 Q4 | 10.44 Million USD | -58.15% |
| 2017 Q2 | 5.9 Million USD | -81.95% |
| 2017 Q1 | 32.69 Million USD | 15.59% |
| 2017 FY | 73.99 Million USD | 38.69% |
| 2017 Q3 | 24.95 Million USD | 322.74% |
| 2016 Q1 | -897 Thousand USD | -175.19% |
| 2016 Q4 | 28.28 Million USD | 129.82% |
| 2016 Q3 | 12.3 Million USD | -9.87% |
| 2016 Q2 | 13.65 Million USD | 1622.41% |
| 2016 FY | 53.35 Million USD | 1984.02% |
| 2015 Q4 | 1.19 Million USD | 111.48% |
| 2015 FY | 2.56 Million USD | 113.65% |
| 2015 Q3 | -10.38 Million USD | -24.63% |
| 2015 Q2 | -8.33 Million USD | -141.49% |
| 2015 Q1 | 20.09 Million USD | 406.02% |
| 2014 Q3 | -9.1 Million USD | -205.32% |
| 2014 FY | -18.75 Million USD | -121.84% |
| 2014 Q4 | -6.56 Million USD | 27.9% |
| 2014 Q2 | -2.98 Million USD | 17.22% |
| 2014 Q1 | -3.6 Million USD | -17.54% |
| 2013 Q2 | 1.25 Million USD | 129.25% |
| 2013 Q1 | -4.3 Million USD | -49.65% |
| 2013 Q3 | -2.53 Million USD | -300.94% |
| 2013 FY | -8.45 Million USD | 57.36% |
| 2013 Q4 | -3.06 Million USD | -21.1% |
| 2012 Q3 | -3.91 Million USD | 0.0% |
| 2012 Q4 | -2.87 Million USD | 26.55% |
| 2012 FY | -19.83 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 67.984% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | 2225.224% |
| Embecta Corp. | 221.5 Million USD | 75.867% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 39.032% |
| PainReform Ltd. | -9.58 Million USD | 657.742% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 1217.046% |
| SCYNEXIS, Inc. | 72.66 Million USD | 26.442% |
| Journey Medical Corporation | -2.07 Million USD | 2678.582% |
| Safety Shot Inc | -12.18 Million USD | 538.717% |
| Alpha Teknova, Inc. | -35.56 Million USD | 250.308% |
| Bright Green Corporation | -8.89 Million USD | 701.189% |
| Procaps Group, S.A. | 38.97 Million USD | -37.156% |
| Alvotech | -354.86 Million USD | 115.063% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | -13.802% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 453.953% |
| Cosmos Health Inc. | -21.83 Million USD | 344.851% |
| Dynavax Technologies Corporation | -37.02 Million USD | 244.361% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 134.362% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 133.539% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 1217.046% |
| Theratechnologies Inc. | -10.62 Million USD | 603.002% |
| Harrow Health, Inc. | 580 Thousand USD | -9116.207% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | 1237.077% |
| Biofrontera Inc. | -22.67 Million USD | 335.719% |
| DURECT Corporation | -36.88 Million USD | 244.925% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 1114.5% |
| Cronos Group Inc. | -81.37 Million USD | 165.688% |
| OptiNose, Inc. | -22.74 Million USD | 334.983% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 74.428% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 236.526% |
| RedHill Biopharma Ltd. | 12.63 Million USD | -323.163% |
| Organogenesis Holdings Inc. | 12.52 Million USD | -326.778% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | 1332.705% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 960.659% |
| Radius Health, Inc. | -3.92 Million USD | 1461.885% |
| Universe Pharmaceuticals INC | -3.52 Million USD | 1615.663% |
| ProPhase Labs, Inc. | -21.61 Million USD | 347.323% |
| Phibro Animal Health Corporation | 53.31 Million USD | -0.261% |
| Procaps Group S.A. | 52.32 Million USD | -2.16% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 727.174% |
| Viatris Inc. | 766.2 Million USD | 93.023% |
| Rockwell Medical, Inc. | -6.67 Million USD | 901.409% |
| Aytu BioPharma, Inc. | -5.25 Million USD | 1117.396% |
| SIGA Technologies, Inc. | 83.62 Million USD | 36.076% |
| Tilray Brands, Inc. | -174.74 Million USD | 130.59% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | -472.865% |
| Shineco, Inc. | -17.06 Million USD | 413.222% |
| PetIQ, Inc. | 60.01 Million USD | 10.932% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | 1228.501% |
| Incannex Healthcare Limited | -30.04 Million USD | 277.937% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 78.695% |
| Alimera Sciences, Inc. | -1.47 Million USD | 3733.855% |
| Silver Spike Investment Corp. | 7.34 Million USD | -628.245% |
| Assertio Holdings, Inc. | -243.53 Million USD | 121.949% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 1007.172% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 492.543% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | 442.786% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 366.603% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 138.777% |
| Hempacco Co., Inc. | -8.81 Million USD | 706.585% |
| Talphera, Inc. | -16.88 Million USD | 416.502% |
| Alvotech | -354.86 Million USD | 115.063% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 85.341% |
| Currenc Group, Inc. | -6.64 Million USD | 904.329% |
| Kamada Ltd. | 10.06 Million USD | -431.141% |
| Indivior PLC | -4 Million USD | 1436.35% |
| Evoke Pharma, Inc. | -7.43 Million USD | 819.348% |
| Flora Growth Corp. | -50.35 Million USD | 206.156% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 366.603% |
| Evolus, Inc. | -49.23 Million USD | 208.574% |
| HUTCHMED (China) Limited | 18.37 Million USD | -190.906% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 72.864% |
| Akanda Corp. | -10.05 Million USD | 631.808% |